With Vicept Buy, Allergan Gains Rosacea Treatment Under Development
This article was originally published in The Rose Sheet
Executive Summary
Drug firm Allergan Inc. has a daily rosacea treatment in the development pipeline following its acquisition of privately held specialty biopharmaceutical firm Vicept Therapeutics in July.
You may also be interested in...
AcneFree Purchase Builds U.S. Scale For Canadian Dermatology Firm
The addition of AcneFree to Valeant Pharma’s OTC portfolio will complement the Montreal firm’s CeraVe skin hydration line and augment its shelf space in U.S. retail doors. Valeant announced $64 million purchase from University Medical earlier this month.
Deals Of The Week: Eisai/Epizyme, AstraZeneca/Galderma, Evotec/Harvard
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
GSK Gains Foothold In U.S. Skin Care With Stiefel Deal
GlaxoSmithKline will more than double its dermatology sales to $1.5 billion with the acquisition of Stiefel Laboratories, a move that provides GSK a foothold in the U.S. market for nonprescription skin-care products